News & Events

News &
Events

Tarsier Pharma to Present at UCLA/AUS 2nd International Workshop on Objective Measures of Intraocular Inflammation for Use in Clinical Trials

September 27-28, 2024

Tarsier Pharma, Ltd. is pleased to announce its participation in the UCLA/AUS 2nd International Workshop on Objective Measures of Intraocular Inflammation for Use in Clinical Trials, scheduled for September 27-28, 2024, in Los Angeles, California.

Prof. Marc de Smet, MD, PhD, Advisor at Tarsier Pharma, will present an abstract titled “Quantification of Anterior Chamber Cells Through an Image-Based Grading Scale.” This presentation will provide valuable insights into innovative techniques for the objective quantification of intraocular inflammation.

The UCLA/AUS 2nd International Workshop on Objective Measures of Intraocular Inflammation for Use in Clinical Trials, is aimed at ophthalmologists, including uveitis specialists, retina specialists, pediatric ophthalmologists, clinical trialists, and representatives from the pharmaceutical and device industries. The workshop’s goals include reviewing proposed clinical outcome measures for uveitis research, progress toward standardization and validation of techniques since 2019, and discussing future study plans. Additionally, FDA representatives will comment on regulatory issues related to the use of devices and incorporation of objective measures into clinical trials.

About Tarsier Pharma

Tarsier Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat immune-mediated blinding diseases in the front and back of the eye.

Contact:

Investor Relations Tarsier Pharma

[email protected]

Scroll to Top